OBJECTIVE: To probe into the efficacy of recombinant human endostatin combined with loboplatin in the treatment of malignant thoracic fluid and its effects on vascular endothelial growth factor（ VEGF） and carcinoembryonic antigen（ CEA）

immune status and prognosis.METHODS: Totally 60 patients with malignant thoracic fluid admitted into Jiangsu Shengze Hospital from Jan.2013 to Dec.2018 were extracted to be divided into the observation group and the control group according to the different treatment schemes

with 60 cases in each group.All patients were given chest cavity puncture tubes

fully drained chest water drain edgy fluid.Patients in the observation group were treated with recombinant human endostatin 60 mg（ twice a week for 2 weeks） + loboplatin 30 mg/m

2

（ once a week for 2 weeks） for intrapleural chemotherapy.The control group received thoracic fluid chemotherapy with loproplatin 30 mg/m

2

once a week for 2 weeks.The clinical efficacy

quanlity of life and adverse drug reactions of two groups were observed.The levels of thoracic fluid VEGF and CEA

the levels of peripheral blood lymphocyte subsets and immunoglobulin[immunoglobulin A（ IgA）

immunoglobulin G（ IgG） and immunoglobulin M（ IgM） ] of two groups were compared.RESULTS: After treatment of 7 d

the levels of VEGF and CEA in thoracic fluid of two groups decreased significantly

and the levels of CD3

+

CD4

+

CD4

+

/CD8

+

IgG and IgA in the peripheral blood increased significantly

and the levels of CD8

+

decreased significantly

the differences were statistically significant（ P

<

0.05）.Compared with the control group

the levels of VEGF and CEA in thoracic fluid in the observation group reduced significantly

and the peripheral blood lymphocyte subsets and immunoglobulin were significantly improved

with statistically significant differences（ P

<

0.05）.However

there was no significant difference in IgM between two groups（ P

>

0.05）.The total effective rate of the observation group was 63.33%（ 19/30）

significantly higher than that of the control group 36.67%（ 11/30）

the difference was statistically significant（ P

<

0.05）.The improvement rate of the quality of life of the observation group was significantly higher than that of the control group

the decline rate of the quality of life was significantly lower than that of the control group

and the PFS was significantly longer than that of the control group

the differences were statistically significant（ P

<

0.05）.The difference in the incidence of adverse drug reactions between two groups was not statistically significant（ P

>

0.05）.CONCLUSIONS: Recombinant human endostatin combined with lobaplatin in the treatment of malignant thoracic fluid has synergy effects

with improved quality of life

few adverse drug reactions

reduced thoracic fluid VEGF and CEA levels and improved immune function.